Press releases

2 February, 2017

Regulatory

NeuroVive’s new generation of sanglifehrin-based compounds demonstrate potent inhibitory effects on human hepatocellular cancer cells

Lund, Sweden, February 2, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, presents preclinical data from a new generation of sanglifehrin- ...

25 January, 2017

Regulatory

NeuroVive redirects research resources from Asian subsidiary to parent

Lund, Sweden, January 25, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that its Taiwan-based subsidiary's research reso ...

23 January, 2017

Regulatory

NeuroVive signs mitochondrial medicine research agreement with US key opinion leader

Lund, Sweden, January 23, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), today announces that NeuroVive has signed a preclinical collaboration agreement with the Children's ...

19 January, 2017

Regulatory

NeuroVive presents positive preclinical data in hepatocellular cancer at HCC Summit

Lund, Sweden, January 19, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that an abstract with novel preclinical cancer d ...

10 January, 2017

Regulatory

NeuroVive signs collaboration agreement with Karolinska Institutet

Lund, Sweden, January 10, 2017 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that a collaboration agreement has been signed w ...

1 November, 2016

Regulatory

NeuroVive reports positive pre-clinical results in NASH

Lund, Sweden, November 1, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced positive pre-clinical results with one of its cy ...

25 October, 2016

Regulatory

NeuroVive completes closure of Lyon subsidiary

Lund, Sweden, October 25, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that it has completed the closure of its dormant ...

21 October, 2016

Regulatory

NeuroVive and Arbutus sign termination agreement

Lund, Sweden, October 21, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that the license agreement with Arbutus Biopharm ...

13 October, 2016

Regulatory

NeuroVive discontinues development of CicloMulsion for acute kidney injury

Lund, Sweden, October 13, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced results from the exploratory clinical phase II s ...

9 August, 2016

Regulatory

NeuroVive’s novel strategy for treatment of mitochondrial disease published in Nature Communications

Lund, Sweden, August 9, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that research results from the NVP015 program inve ...

6 July, 2016

Regulatory

NeuroVive announces Arbutus Biopharma’s notice of termination

Lund, Sweden, July 6, 2016 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announces that Arbutus Biopharma (formerly OnCore Biopharma, I ...

7 June, 2016

Regulatory

NeuroVive announces CiPRICS study completes enrolment

Lund, Sweden, 7 June 2016 - NeuroVive Pharmaceutical AB (publ), announces that the CiPRICS (Ciclosporin to Protect Renal function In Cardiac Surgery) clinical research team at the Department of Cardio ...